Press release
September 28, 2026
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
Biohaven Ltd. (BHVN)
We couldn't retrieve the full text for this release. Read it on the company's site.